

Claims

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of
 - i) contacting a test compound with a FPRL2 polypeptide,
 - ii) detect binding of said test compound to said FPRL2 polypeptide.
2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of
 - i) determining the activity of a FPRL2 polypeptide at a certain concentration of a test compound or in the absence of said test compound,
 - ii) determining the activity of said polypeptide at a different concentration of said test compound.
3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of
 - i) determining the activity of a FPRL2 polypeptide at a certain concentration of a test compound,

- ii) determining the activity of a FPRL2 polypeptide at the presence of a compound known to be a regulator of a FPRL2 polypeptide.
- 4. The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.
5
- 5. The method of any of claims 1 to 3, wherein the cell is in vitro.
- 6. The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.
10
- 7. The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.
- 15 8. The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.
- 9. The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.
20
- 10. The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.
- 25 11. The method of any of claims 1 to 3, wherein the compound is attached to a solid support.
- 12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of
30

- i) contacting a test compound with a FPRL2 polynucleotide,
- ii) detect binding of said test compound to said FPRL2 polynucleotide.

5 13. The method of claim 12 wherein the nucleic acid molecule is RNA.

14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.

10 15. The method of claim 12 wherein the contacting step is in a cell-free system.

16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.

15 17. The method of claim 12 wherein the test compound is coupled to a detectable label.

18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of

20 i) determining the amount of a FPRL2 polynucleotide in a sample taken from said mammal,

25 ii) determining the amount of FPRL2 polynucleotide in healthy and/or diseased mammals.

30 19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory

diseases in a mammal comprising a therapeutic agent which binds to a FPRL2 polypeptide.

20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising a therapeutic agent which regulates the activity of a FPRL2 polypeptide.

5 10 21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising a therapeutic agent which regulates the activity of a FPRL2 polypeptide, wherein said therapeutic agent is

15
i) a small molecule,
ii) an RNA molecule,
iii) an antisense oligonucleotide,
iv) a polypeptide,
20 v) an antibody, or
vi) a ribozyme.

25 22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising a FPRL2 polynucleotide.

30 23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising a FPRL2 polypeptide.

24. Use of regulators of a FPRL2 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal.

5 25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of

10 i) identifying a regulator of FPRL2,

15 ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal; and

20 iii) combining of said regulator with an acceptable pharmaceutical carrier.

26. Use of a regulator of FPRL2 for the regulation of FPRL2 activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases.